AzTrials
AzTrials

Central Neuropathic PainPhase 4NCT00313820

Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain

A Phase 4 study testing Pregabalin in people with Central Neuropathic Pain, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 33 sites in 11 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Efficacy and Safety of flexibly dosed pregabalin compared to placebo among subjects with central post stroke pain (CPSP) Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Central Neuropathic Pain
What is being tested?
Pregabalin
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
220 participants
Where
33 sitesin 11 countries
Study dates
Aug 2006to Sep 2008
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Positive history of clinical stroke at least 4 months prior to randomization CPSP--3 months prior to screening

Who cannot join

  • History of dementia or any other severe cognitive impairment
  • Diabetic Peripheral Neuropathy (DPN)

Trial locations and contacts

33 sites in 11 countries.

33 sites in 11 countries

Australia7 sites
  • Pfizer Investigational Site

    Darlinghurst, New South Wales, 2010

  • Pfizer Investigational Site

    East Gosford, New South Wales, 2250

  • Pfizer Investigational Site

    Footscray, Victoria, 3011

  • Pfizer Investigational Site

    Herston, Queensland

  • Pfizer Investigational Site

    Perth, Western Australia, 6000

  • Pfizer Investigational Site

    St Leonards, New South Wales, 2065

  • Pfizer Investigational Site

    Warrawong, New South Wales, 2502

Other trials in Australia

China5 sites
  • Pfizer Investigational Site

    Beijing, 100083

  • Pfizer Investigational Site

    Beijing, 100730

  • Pfizer Investigational Site

    Guangzhou, 510180

  • Pfizer Investigational Site

    Shanghai, 200003

  • Pfizer Investigational Site

    Shanghai, 200040

Other trials in China

India5 sites
  • Pfizer Investigational Site

    Bangalore, 560 034

  • Pfizer Investigational Site

    Bangalore, 560 054

  • Pfizer Investigational Site

    Chennai, 600 010

  • Pfizer Investigational Site

    Lucknow, 226 014

  • Pfizer Investigational Site

    New Delhi, 110 002

Other trials in India

Malaysia3 sites
  • Pfizer Investigational Site

    George Town, 11600

  • Pfizer Investigational Site

    Kuala Lumpur, 59100

  • Pfizer Investigational Site

    Kuala Selangor, 68100

Other trials in Malaysia

Taiwan3 sites
  • Pfizer Investigational Site

    Gueishan Shiang, Taoyuan Hsien

  • Pfizer Investigational Site

    Taichung, 407

  • Pfizer Investigational Site

    Taipei, 112

Other trials in Taiwan

Indonesia2 sites
  • Pfizer Investigational Site

    Jakarta, 10430

  • Pfizer Investigational Site

    Surabaya, 60286

Other trials in Indonesia

Pakistan2 sites
  • Pfizer Investigational Site

    Karachi, Sindh

  • Pfizer Investigational Site

    Karachi

Other trials in Pakistan

Philippines2 sites
  • Pfizer Investigational Site

    Manila, 1000

  • Pfizer Investigational Site

    Manila, 1003

Other trials in Philippines

Thailand2 sites
  • Pfizer Investigational Site

    Bangkok, 10400

  • Pfizer Investigational Site

    Ratchatewee, Bangkok, 10400

Other trials in Thailand

Hong Kong1 site
  • Pfizer Investigational Site

    New Territories

Other trials in Hong Kong

South Korea1 site
  • Pfizer Investigational Site

    Seoul, 138-736

Other trials in South Korea

About this study

Official title: A 13-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150-600 Mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Central Post-Stroke Pain (CPSP)

Efficacy and Safety of flexibly dosed pregabalin compared to placebo among subjects with central post stroke pain (CPSP)

Being tested
Pregabalin, Placebo
Keywords
Post-stroke pain, pregabalin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PregabalinDrug

    Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.

  • PlaceboDrug

    Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.

Study groups in NCT00313820
Study groupRoleWhat they receive
PregabalinActive comparatorThe change from in pain scores from baseline to endpoint among stroke subjects receiving pregabalin will be compared to change in pain scores from baseline to endpoint among stroke subjects receiving matched placebo.
Receives: Drug: Pregabalin
PlaceboPlacebo comparatorThe change in pain scores from baseline to endpoint will be compared among the two treatment groups- ie subjects receiving 12 weeks of pregabalin treatment vs subjects receiving 12 weeks of placebo treatment.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean Pain Score at Endpoint as Measured by Daily Pain Rating Scale (DPRS)

    Mean pain score obtained from last 7 available DPRS scores up to and including day of Week 12 visit or early termination (ET) equivalent. DPRS: subject rated 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain) during past 24-hour period. Higher score indicates greater level of pain. Self-assessment performed daily on awakening prior to taking study medication.

    Measured: Up to Week 12

Secondary outcomes (15)
  1. Pain Score as Measured by DPRS

    Weekly mean pain score measured by DPRS: subject rated 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain) during past 24-hour period. Higher score indicates greater level of pain. Self-assessment performed daily on awakening prior to taking study medication.

    Measured: Week 1, Week 2, Week 3, Week 6, Week 9, and Week 12

  2. Number of Subjects With at Least a 30% Reduction From Baseline in Mean Pain Score at Endpoint

    30% Responder Yes = number of subjects with 30% reduction in mean pain score from baseline to observation; 30% reduction calculated as [(T minus B) divided by B multiplied by 100] < = negative 30. T = endpoint mean pain score (obtained from last 7 available scores from DPRS); B = baseline mean pain score (obtained from average of last 7 daily scores from DPRS). 30% Responder No indicates number of subjects that did not reach 30% reduction in mean pain score.

    Measured: Baseline, Week 12

  3. Number of Subjects With at Least a 50% Reduction From Baseline in Mean Pain Score at Endpoint

    50% Responder Yes = number of subjects with 50% reduction in mean pain score from baseline to observation; 50% reduction calculated as [(T minus B) divided by B multiplied by 100] < = negative 50. T = endpoint mean pain score (obtained from last 7 available scores from DPRS); B = baseline mean pain score (obtained from average of last 7 daily scores from DPRS). 50% Responder No indicates number of subjects that did not reach 50% reduction in mean pain score.

    Measured: Baseline, Week 12

  4. Weekly Mean Sleep Interference Score From Daily Sleep Diary (Daily Sleep Interference Scale [DSIS])

    DSIS: subject rated 11-point numeric scale ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep) during past 24-hour period. Higher score indicates a greater level of sleep disturbance. Self-assessment performed daily on awakening prior to taking study medication. Endpoint calculated as mean of last 7 available scores.

    Measured: Week 1, Week 2, Week 3, Week 6, Week 9, and Week 12

  5. Short Form-McGill Pain Questionnaire (SF-MPQ Visual Analog Scale [VAS]) - Part B Only

    SF-MPQ Part B VAS consists of a line 0 to 100 millimeters (mm) in length; range is (no pain) to 100 mm (worst possible pain). Subjects placed a mark indicating the intensity of their pain. Distance from left-hand end of line was measured and entered on Case Report Form (CRF) as score in mm. Higher score indicates greater level of pain.

    Measured: Week 12

  6. Neuropathic Pain Symptom Inventory (NPSI)

    NPSI: subject rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score (0 to 100). Higher score indicates a greater intensity of pain.

    Measured: Week 12

  7. Medical Outcome Study (MOS) Sleep Scale

    MOS: subject rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute.

    Measured: Week 12

  8. Number of Subjects With Yes or No Response for Medical Outcome Study (MOS) Sleep Scale - Optimal Sleep

    MOS: subject rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Number of subjects with response = YES if sleep quantity is 7 or 8 hours per night or response = NO if sleep quantity is < 7 hours per night.

    Measured: Week 12

  9. Hospital Anxiety and Depression Scale (HADS) - ITT Population

    HADS is subject rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Measured: Week 12

  10. Euro Quality of Life (EQ-5D)- Health State Profile Utility Score

    EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Week 12

  11. EQ-5D - VAS

    EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

    Measured: Week 12

  12. Patient Global Impression of Change (PGIC)

    PGIC: subject rated instrument to measure subject's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).

    Measured: Week 12

  13. Clinical Global Impression of Change (CGIC)

    CGIC: clinician rated instrument that measures change in a subject's ovall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).

    Measured: Week 12

  14. Quantitative Assessment of Neuropathic Pain (QANeP) - Sensory Threshold

    QANeP: assessment of sensory threshold: subject responds "yes" when monofilament stimulus is felt on area of maximum pain: 1 (lowest/softest 0.07 gram [g]) to 6 (highest 300 g) or 7 (not perceived); rated by lowest/softest filament felt when in contact with the skin. Summarized as change from baseline (mean at observation minus mean at baseline).

    Measured: Baseline, Week 12

  15. QANeP - Pain Rating Scales

    Subject rated pain scale: static mechanical allodynia (SMA) gentle constant mechanical pressure; dynamic mechanical allodynia (DMA) gentle stroking with foam brush; punctate hyperalgesia (PH) pinprick; cold allodynia (CA) touch with cool metal rod 13-17° celsius (C); cold hyperalgesia (CH) touch with cold metal rod 4° C; temporal summation to tactile stimuli (TSTS) repeated touching/tapping. 11-point numeric scale; range 0 (no pain) to 10 (worst possible pain). Reference area=mirror image of pain site (test area). Summarized as change from baseline (mean at observation minus mean at baseline).

    Measured: Baseline, Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Apr 2006 (estimated)
  2. Study startAug 2006
  3. Primary completionSep 2008
  4. Study completionSep 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
220 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00313820
Sponsor's protocol ID
A0081063
Status last verified
Oct 2009
First submitted
10 Apr 2006
Last updated
9 Feb 2021
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Pregabalin in people with Central Neuropathic Pain, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 33 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 33 sites in Australia, China, India, Malaysia, Taiwan and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Oct 2009). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean Pain Score at Endpoint as Measured by Daily Pain Rating Scale (DPRS) (time frame: Up to Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in